about
Hemostatic abnormalities in critically ill patients.Laser-induced endothelial cell activation supports fibrin formation.Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport.Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.Protein C mutation (A267T) results in ER retention and unfolded protein response activation.Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in ratsTherapeutic interventions in sepsis: current and anticipated pharmacological agentsGenome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.Pathophysiology of the antiphospholipid antibody syndrome.Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.A novel heparin-dependent inhibitor of activated protein C that potentiates consumptive coagulopathy in Russell's viper envenomation.Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome.Protective mechanisms of activated protein C in severe inflammatory disorders.Management of inherited thrombophilia in pregnancy.Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndromeRecombinant thrombomodulin of different domains for pharmaceutical, biomedical, and cell transplantation applications.The pathogenesis of traumatic coagulopathy.Factor V Leiden.Diagnosis and management of factor V Leiden.Activated protein C does not increase in the early phase of trauma with disseminated intravascular coagulation: comparison with acute coagulopathy of trauma-shock.Human activated protein C variants in a rat model of arterial thrombosis.Platelet factor 4 impairs the anticoagulant activity of activated protein C.Novel association of a PROC variant with ischemic stroke in a Chinese Han population.An analysis of the levels of the soluble form of the endothelial protein C receptor in children with Henoch-Schönlein Purpura.ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation.Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications.Innate immune response gene expression profiles characterize primary antiphospholipid syndrome.Thrombin activation of protein C requires prior processing by a liver proprotein convertase.Activated protein C is released from PROCRActivation of matrix metalloproteinases 2, 9, and 13 by activated protein C in human osteoarthritic cartilage chondrocytes.Molecular dynamics and docking simulation of a natural variant of Activated Protein C with impaired protease activity: implications for integrin-mediated antiseptic function.Activated protein C plays no major roles in the inhibition of coagulation or increased fibrinolysis in acute coagulopathy of trauma-shock: a systematic review.
P2860
Q33419474-D43DDF23-3D19-4295-AEA7-0291DE75C96DQ33646447-54687306-1AD7-4EE1-B4B6-C2D1D9B8245FQ33684074-5AFB6C0D-4356-408A-8112-38EBAA3B212EQ33748551-D72A3FA4-6146-45A0-9708-B2D3BEAC297FQ34006140-E0B213FE-B3E2-4276-A018-4300D1F61E85Q34013789-583DE39F-57DC-42A9-B846-36B521D0D87FQ34074200-7717DFC0-0DFE-47C4-AF56-0BA7FD8FA9CAQ34427050-AE895715-48D1-4380-9642-70EC361F9A3DQ34450740-0C4D18F5-22A4-478F-B0DE-5E50E50054D4Q34501341-8AD473DF-67E0-4B3D-AFA2-CAFBBCCFA808Q35309024-ACB8B87B-AF1E-4C53-A0D9-2625BCA36DFBQ35567223-AB1CD711-3EED-45F0-A4F7-5DC253276744Q35940022-436767D8-ACC7-4516-9B1F-BD7FC4254C0CQ36749051-D6202654-2CF5-4417-8A94-347DAE99DBE4Q37290460-B9BF629D-C26B-4984-85AD-E0BFC0040D16Q37494702-9C50E0A0-04A7-405D-B1CB-ADD7F264D609Q37730086-B4D7908A-A74F-4373-931F-2FCE6E18EFB9Q37852747-E009EF8E-D7AF-4391-91CA-F600C4D78856Q38117276-31991621-7813-4933-8A12-0A05DC17745CQ38273793-19D76ACA-5D5C-4F8D-8BEB-6E36A54B1470Q38613917-09DEE9C5-2817-4E11-B9C2-9B36D3A0584EQ38994953-1B01754F-8FEB-40E1-BE2F-1C0722A246A1Q41832671-AB2FA3FA-F024-4574-914F-BD96E20EB581Q42009597-339B5566-657B-4CBB-8782-90D97653594AQ43667908-A21CCF45-4EF7-4858-89AF-29D0FB9C7103Q44137280-BDE85EF9-E947-43E1-9778-B15CCA1E9418Q45067101-8DD64DFD-864C-4112-8597-C8248C09DB4DQ46280873-F89089F2-4DA7-4E1D-889F-7C2FB569C9ABQ46901004-424D740A-67ED-4FFE-8391-D80EAF5834C8Q47126623-2AD5B719-333B-4F1E-A01E-623D77CD5D07Q47743642-7779E845-0393-43FE-BB0C-BA47EB79426DQ48197704-E9195433-FF82-4C28-91C5-C5E2D48D3BF1Q50291225-25E5049D-6007-4082-AFF5-C23275177C23Q53064724-5896823A-C022-42AA-80DF-BF7D217C2276Q54572577-CA15E99C-6C7C-40C8-8F90-7DEBD46FB220Q55312148-B9A9FD56-F8C5-4794-A897-83209AF85539
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activated protein C.
@en
type
label
Activated protein C.
@en
prefLabel
Activated protein C.
@en
P2093
P2860
P1476
Activated protein C.
@en
P2093
Fernández JA
Griffin JH
Mosnier LO
P2860
P356
10.1111/J.1538-7836.2007.02491.X
P478
P577
2007-07-01T00:00:00Z